Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02YFZ
|
|||
| Former ID |
DNC011916
|
|||
| Drug Name |
2-Piperazin-1-yl-benzonitrile
|
|||
| Synonyms |
1-(2-Cyanophenyl)piperazine; 111373-03-6; 2-(piperazin-1-yl)benzonitrile; 2-piperazin-1-ylbenzonitrile; 2-(1-Piperazino)benzonitrile; Benzonitrile, 2-(1-piperazinyl)-; 2-Piperazin-1-yl-benzonitrile; 1-(2-Cyanophenyl)-piperazine; 2-(1-piperazinyl)benzonitrile; CHEMBL275943; 2-piperazinylbenzenecarbonitrile; PubChem9347; 2-Piperazinobenzonitrile; AC1MC4BA; AC1Q4R0F; (2-cyano-phenyl)-piperazine; KSC491G1H; SCHEMBL233169; 1-(2-cyanophenyl) piperazine; ACMC-20999f; 1-(2-cyano phenyl) piperazine; Jsp000853
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H13N3
|
|||
| Canonical SMILES |
C1CN(CCN1)C2=CC=CC=C2C#N
|
|||
| InChI |
1S/C11H13N3/c12-9-10-3-1-2-4-11(10)14-7-5-13-6-8-14/h1-4,13H,5-8H2
|
|||
| InChIKey |
FRICBZWJFIRJOB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 111373-03-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 1A receptor (HTR1A) | Target Info | Inhibitor | [1] |
| 5-HT 1D receptor (HTR1D) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT1 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | |||
| SIDS Susceptibility Pathways | ||||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.